Necrotizing Gingivostomatitis Treatment Market Size & Share, by Type {Necrotizing Ulcerative Gingivitis (NUG), Necrotizing Ulcerative Periodontitis (NUP), Necrotizing Stomatitis (NS)}; Treatment (Antiseptic Rinses, Antibiotics, Gingival Grafting); Distribution Channel (Hospital Pharmacies, Medical Store, Online) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3570
  • Published Date: Mar 30, 2023
  • Report Format: PDF, PPT

Companies Dominating the Necrotizing Gingivostomatitis Treatment Landscape

top-features-companies
    • Novartis International AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Sanofi S.A.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Abbott Laboratories
    • Eli Lilly and Company
    • Hindustan Antibiotics Limited
    • Aviro Health L.P.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • GlaxoSmithKline plc conducted an online survey in five European countries with 4,500 people to study the relationship between poor oral hygiene and disease complications. The conclusion of the study showed that there was a need to raise public awareness regarding the impact of oral hygiene on overall health.

  • Aviro Health L.P. declared that it granted the award of investigator-initiated research (IIR) grant to the University of Pennsylvania School of Dental Medicine Center for Clinical and Translational Research to investigate and report the effectiveness of povidone-iodine antiseptic oral rinse in removing COVID-19 virus or SARS-CoV-2 virus in the mouth.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3570
  • Published Date: Mar 30, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of necrotizing gingivostomatitis and the rising use of public toilets are the major factors driving the market growth.

The market size of necrotizing gingivostomatitis treatment is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2035.

Circulation of generic drugs, and side effects of antibiotics are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd, Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics Limited, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, treatment, distribution channel, and by region.

The antiseptic rinses segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying